

# Global Recurrent Glioblastoma Multiforme Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/GADAB4763A08EN.html>

Date: June 2024

Pages: 132

Price: US\$ 3,480.00 (Single User License)

ID: GADAB4763A08EN

## Abstracts

According to our (Global Info Research) latest study, the global Recurrent Glioblastoma Multiforme Treatment market size was valued at USD 476.8 million in 2023 and is forecast to a readjusted size of USD 702.6 million by 2030 with a CAGR of 5.7% during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Recurrent Glioblastoma Multiforme Treatment industry chain, the market status of Hospital (AU-105, Axitinib), Clinic (AU-105, Axitinib), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot

applications and market trends of Recurrent Glioblastoma Multiforme Treatment.

Regionally, the report analyzes the Recurrent Glioblastoma Multiforme Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Recurrent Glioblastoma Multiforme Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Recurrent Glioblastoma Multiforme Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Recurrent Glioblastoma Multiforme Treatment industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., AU-105, Axitinib).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Recurrent Glioblastoma Multiforme Treatment market.

**Regional Analysis:** The report involves examining the Recurrent Glioblastoma Multiforme Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Recurrent Glioblastoma Multiforme Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Recurrent Glioblastoma Multiforme Treatment:

**Company Analysis:** Report covers individual Recurrent Glioblastoma Multiforme Treatment players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Recurrent Glioblastoma Multiforme Treatment. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

**Technology Analysis:** Report covers specific technologies relevant to Recurrent Glioblastoma Multiforme Treatment. It assesses the current state, advancements, and potential future developments in Recurrent Glioblastoma Multiforme Treatment areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Recurrent Glioblastoma Multiforme Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

## Market Segmentation

Recurrent Glioblastoma Multiforme Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

### Market segment by Type

AU-105

Axitinib

AXL-1717

AZD-7451

Others

#### Market segment by Application

Hospital

Clinic

Others

#### Market segment by players, this report covers

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Cavion LLC

Celldex Therapeutics, Inc.

Coherus BioSciences, Inc.

Cortice Biosciences, Inc.

Eisai

Eli Lilly and Company

EnGeneIC Ltd

ERC Belgium SA

GenSpera, Inc.

Genzyme Corporation

GW Pharmaceuticals Plc

ImmunoCellular Therapeutics, Ltd.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Recurrent Glioblastoma Multiforme Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Recurrent Glioblastoma Multiforme Treatment, with revenue, gross margin and global market share of Recurrent Glioblastoma Multiforme Treatment from 2019 to 2024.

Chapter 3, the Recurrent Glioblastoma Multiforme Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024. and Recurrent Glioblastoma Multiforme Treatment market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Recurrent Glioblastoma Multiforme Treatment.

Chapter 13, to describe Recurrent Glioblastoma Multiforme Treatment research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Recurrent Glioblastoma Multiforme Treatment

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Recurrent Glioblastoma Multiforme Treatment by Type

1.3.1 Overview: Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type: 2019 Versus 2023 Versus 2030

1.3.2 Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type in 2023

1.3.3 AU-105

1.3.4 Axitinib

1.3.5 AXL-1717

1.3.6 AZD-7451

1.3.7 Others

1.4 Global Recurrent Glioblastoma Multiforme Treatment Market by Application

1.4.1 Overview: Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application: 2019 Versus 2023 Versus 2030

1.4.2 Hospital

1.4.3 Clinic

1.4.4 Others

1.5 Global Recurrent Glioblastoma Multiforme Treatment Market Size & Forecast

1.6 Global Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast by Region

1.6.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region: 2019 VS 2023 VS 2030

1.6.2 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region, (2019-2030)

1.6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2019-2030)

1.6.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2019-2030)

1.6.5 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2019-2030)

1.6.6 South America Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2019-2030)

1.6.7 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Market Size and Prospect (2019-2030)

## 2 COMPANY PROFILES

### 2.1 Boehringer Ingelheim GmbH

2.1.1 Boehringer Ingelheim GmbH Details

2.1.2 Boehringer Ingelheim GmbH Major Business

2.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.1.4 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans

### 2.2 Boston Biomedical, Inc.

2.2.1 Boston Biomedical, Inc. Details

2.2.2 Boston Biomedical, Inc. Major Business

2.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.2.4 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.2.5 Boston Biomedical, Inc. Recent Developments and Future Plans

### 2.3 Bristol-Myers Squibb Company

2.3.1 Bristol-Myers Squibb Company Details

2.3.2 Bristol-Myers Squibb Company Major Business

2.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.3.4 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.3.5 Bristol-Myers Squibb Company Recent Developments and Future Plans

### 2.4 Cantex Pharmaceuticals, Inc.

2.4.1 Cantex Pharmaceuticals, Inc. Details

2.4.2 Cantex Pharmaceuticals, Inc. Major Business

2.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.4.4 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.4.5 Cantex Pharmaceuticals, Inc. Recent Developments and Future Plans

### 2.5 Cavion LLC

2.5.1 Cavion LLC Details

2.5.2 Cavion LLC Major Business

2.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product and Solutions



2.5.4 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.5.5 Cavion LLC Recent Developments and Future Plans

2.6 Celldex Therapeutics, Inc.

2.6.1 Celldex Therapeutics, Inc. Details

2.6.2 Celldex Therapeutics, Inc. Major Business

2.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.6.4 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.6.5 Celldex Therapeutics, Inc. Recent Developments and Future Plans

2.7 Coherus BioSciences, Inc.

2.7.1 Coherus BioSciences, Inc. Details

2.7.2 Coherus BioSciences, Inc. Major Business

2.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.7.4 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.7.5 Coherus BioSciences, Inc. Recent Developments and Future Plans

2.8 Cortice Biosciences, Inc.

2.8.1 Cortice Biosciences, Inc. Details

2.8.2 Cortice Biosciences, Inc. Major Business

2.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.8.4 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.8.5 Cortice Biosciences, Inc. Recent Developments and Future Plans

2.9 Eisai

2.9.1 Eisai Details

2.9.2 Eisai Major Business

2.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.9.4 Eisai Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.9.5 Eisai Recent Developments and Future Plans

2.10 Eli Lilly and Company

2.10.1 Eli Lilly and Company Details

2.10.2 Eli Lilly and Company Major Business

2.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions

- 2.10.4 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Eli Lilly and Company Recent Developments and Future Plans
- 2.11 EnGeneIC Ltd
  - 2.11.1 EnGeneIC Ltd Details
  - 2.11.2 EnGeneIC Ltd Major Business
  - 2.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product and Solutions
  - 2.11.4 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.11.5 EnGeneIC Ltd Recent Developments and Future Plans
- 2.12 ERC Belgium SA
  - 2.12.1 ERC Belgium SA Details
  - 2.12.2 ERC Belgium SA Major Business
  - 2.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product and Solutions
  - 2.12.4 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.12.5 ERC Belgium SA Recent Developments and Future Plans
- 2.13 GenSpera, Inc.
  - 2.13.1 GenSpera, Inc. Details
  - 2.13.2 GenSpera, Inc. Major Business
  - 2.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions
  - 2.13.4 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.13.5 GenSpera, Inc. Recent Developments and Future Plans
- 2.14 Genzyme Corporation
  - 2.14.1 Genzyme Corporation Details
  - 2.14.2 Genzyme Corporation Major Business
  - 2.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product and Solutions
  - 2.14.4 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.14.5 Genzyme Corporation Recent Developments and Future Plans
- 2.15 GW Pharmaceuticals Plc
  - 2.15.1 GW Pharmaceuticals Plc Details
  - 2.15.2 GW Pharmaceuticals Plc Major Business
  - 2.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product

and Solutions

2.15.4 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.15.5 GW Pharmaceuticals Plc Recent Developments and Future Plans

2.16 ImmunoCellular Therapeutics, Ltd.

2.16.1 ImmunoCellular Therapeutics, Ltd. Details

2.16.2 ImmunoCellular Therapeutics, Ltd. Major Business

2.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

2.16.4 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.16.5 ImmunoCellular Therapeutics, Ltd. Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue and Share by Players (2019-2024)

3.2 Market Share Analysis (2023)

3.2.1 Market Share of Recurrent Glioblastoma Multiforme Treatment by Company Revenue

3.2.2 Top 3 Recurrent Glioblastoma Multiforme Treatment Players Market Share in 2023

3.2.3 Top 6 Recurrent Glioblastoma Multiforme Treatment Players Market Share in 2023

3.3 Recurrent Glioblastoma Multiforme Treatment Market: Overall Company Footprint Analysis

3.3.1 Recurrent Glioblastoma Multiforme Treatment Market: Region Footprint

3.3.2 Recurrent Glioblastoma Multiforme Treatment Market: Company Product Type Footprint

3.3.3 Recurrent Glioblastoma Multiforme Treatment Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

### **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption Value and Market Share by Type (2019-2024)

4.2 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast by Type

(2025-2030)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application (2019-2024)

5.2 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast by Application (2025-2030)

## **6 NORTH AMERICA**

6.1 North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2030)

6.2 North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2030)

6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country

6.3.1 North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2030)

6.3.2 United States Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

6.3.3 Canada Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

6.3.4 Mexico Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

## **7 EUROPE**

7.1 Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2030)

7.2 Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2030)

7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country

7.3.1 Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2030)

7.3.2 Germany Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

7.3.3 France Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

7.3.4 United Kingdom Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

7.3.5 Russia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

7.3.6 Italy Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2030)

8.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2030)

8.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region

8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Region (2019-2030)

8.3.2 China Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

8.3.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

8.3.4 South Korea Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

8.3.5 India Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

8.3.6 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

8.3.7 Australia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

## **9 SOUTH AMERICA**

9.1 South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2030)

9.2 South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2030)

9.3 South America Recurrent Glioblastoma Multiforme Treatment Market Size by Country

9.3.1 South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2030)

9.3.2 Brazil Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

9.3.3 Argentina Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2030)

10.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2030)

10.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country

10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2030)

10.3.2 Turkey Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

10.3.3 Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

10.3.4 UAE Recurrent Glioblastoma Multiforme Treatment Market Size and Forecast (2019-2030)

## **11 MARKET DYNAMICS**

11.1 Recurrent Glioblastoma Multiforme Treatment Market Drivers

11.2 Recurrent Glioblastoma Multiforme Treatment Market Restraints

11.3 Recurrent Glioblastoma Multiforme Treatment Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Recurrent Glioblastoma Multiforme Treatment Industry Chain

12.2 Recurrent Glioblastoma Multiforme Treatment Upstream Analysis

12.3 Recurrent Glioblastoma Multiforme Treatment Midstream Analysis

12.4 Recurrent Glioblastoma Multiforme Treatment Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer



## List Of Tables

### LIST OF TABLES

Table 1. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Region (2019-2024) & (USD Million)

Table 4. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Region (2025-2030) & (USD Million)

Table 5. Boehringer Ingelheim GmbH Company Information, Head Office, and Major Competitors

Table 6. Boehringer Ingelheim GmbH Major Business

Table 7. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 8. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 9. Boehringer Ingelheim GmbH Recent Developments and Future Plans

Table 10. Boston Biomedical, Inc. Company Information, Head Office, and Major Competitors

Table 11. Boston Biomedical, Inc. Major Business

Table 12. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 13. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 14. Boston Biomedical, Inc. Recent Developments and Future Plans

Table 15. Bristol-Myers Squibb Company Company Information, Head Office, and Major Competitors

Table 16. Bristol-Myers Squibb Company Major Business

Table 17. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 18. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 19. Bristol-Myers Squibb Company Recent Developments and Future Plans

Table 20. Cantex Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors

Table 21. Cantex Pharmaceuticals, Inc. Major Business



Table 22. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 23. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 24. Cantex Pharmaceuticals, Inc. Recent Developments and Future Plans

Table 25. Cavion LLC Company Information, Head Office, and Major Competitors

Table 26. Cavion LLC Major Business

Table 27. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 28. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 29. Cavion LLC Recent Developments and Future Plans

Table 30. Celldex Therapeutics, Inc. Company Information, Head Office, and Major Competitors

Table 31. Celldex Therapeutics, Inc. Major Business

Table 32. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 33. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 34. Celldex Therapeutics, Inc. Recent Developments and Future Plans

Table 35. Coherus BioSciences, Inc. Company Information, Head Office, and Major Competitors

Table 36. Coherus BioSciences, Inc. Major Business

Table 37. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 38. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 39. Coherus BioSciences, Inc. Recent Developments and Future Plans

Table 40. Cortice Biosciences, Inc. Company Information, Head Office, and Major Competitors

Table 41. Cortice Biosciences, Inc. Major Business

Table 42. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions

Table 43. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 44. Cortice Biosciences, Inc. Recent Developments and Future Plans

Table 45. Eisai Company Information, Head Office, and Major Competitors

Table 46. Eisai Major Business

Table 47. Eisai Recurrent Glioblastoma Multiforme Treatment Product and Solutions

- Table 48. Eisai Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 49. Eisai Recent Developments and Future Plans
- Table 50. Eli Lilly and Company Company Information, Head Office, and Major Competitors
- Table 51. Eli Lilly and Company Major Business
- Table 52. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 53. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 54. Eli Lilly and Company Recent Developments and Future Plans
- Table 55. EnGeneIC Ltd Company Information, Head Office, and Major Competitors
- Table 56. EnGeneIC Ltd Major Business
- Table 57. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 58. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 59. EnGeneIC Ltd Recent Developments and Future Plans
- Table 60. ERC Belgium SA Company Information, Head Office, and Major Competitors
- Table 61. ERC Belgium SA Major Business
- Table 62. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 63. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 64. ERC Belgium SA Recent Developments and Future Plans
- Table 65. GenSpera, Inc. Company Information, Head Office, and Major Competitors
- Table 66. GenSpera, Inc. Major Business
- Table 67. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 68. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 69. GenSpera, Inc. Recent Developments and Future Plans
- Table 70. Genzyme Corporation Company Information, Head Office, and Major Competitors
- Table 71. Genzyme Corporation Major Business
- Table 72. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 73. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

- Table 74. Genzyme Corporation Recent Developments and Future Plans
- Table 75. GW Pharmaceuticals Plc Company Information, Head Office, and Major Competitors
- Table 76. GW Pharmaceuticals Plc Major Business
- Table 77. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 78. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 79. GW Pharmaceuticals Plc Recent Developments and Future Plans
- Table 80. ImmunoCellular Therapeutics, Ltd. Company Information, Head Office, and Major Competitors
- Table 81. ImmunoCellular Therapeutics, Ltd. Major Business
- Table 82. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product and Solutions
- Table 83. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 84. ImmunoCellular Therapeutics, Ltd. Recent Developments and Future Plans
- Table 85. Global Recurrent Glioblastoma Multiforme Treatment Revenue (USD Million) by Players (2019-2024)
- Table 86. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players (2019-2024)
- Table 87. Breakdown of Recurrent Glioblastoma Multiforme Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 88. Market Position of Players in Recurrent Glioblastoma Multiforme Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
- Table 89. Head Office of Key Recurrent Glioblastoma Multiforme Treatment Players
- Table 90. Recurrent Glioblastoma Multiforme Treatment Market: Company Product Type Footprint
- Table 91. Recurrent Glioblastoma Multiforme Treatment Market: Company Product Application Footprint
- Table 92. Recurrent Glioblastoma Multiforme Treatment New Market Entrants and Barriers to Market Entry
- Table 93. Recurrent Glioblastoma Multiforme Treatment Mergers, Acquisition, Agreements, and Collaborations
- Table 94. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value (USD Million) by Type (2019-2024)
- Table 95. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Share by Type (2019-2024)
- Table 96. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value

## Forecast by Type (2025-2030)

Table 97. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2024)

Table 98. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Forecast by Application (2025-2030)

Table 99. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 100. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 101. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 102. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 103. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 104. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 105. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 106. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 107. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 108. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 109. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 110. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 111. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 112. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 113. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 114. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 115. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Region (2019-2024) & (USD Million)

Table 116. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value by Region (2025-2030) & (USD Million)

Table 117. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 118. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 119. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 120. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 121. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 122. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 123. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 124. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 125. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 126. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 127. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 128. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 129. Recurrent Glioblastoma Multiforme Treatment Raw Material

Table 130. Key Suppliers of Recurrent Glioblastoma Multiforme Treatment Raw Materials



## List Of Figures

### LIST OF FIGURES

- Figure 1. Recurrent Glioblastoma Multiforme Treatment Picture
- Figure 2. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 3. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type in 2023
- Figure 4. AU-105
- Figure 5. Axitinib
- Figure 6. AXL-1717
- Figure 7. AZD-7451
- Figure 8. Others
- Figure 9. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 10. Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application in 2023
- Figure 11. Hospital Picture
- Figure 12. Clinic Picture
- Figure 13. Others Picture
- Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value, (USD Million): 2019 & 2023 & 2030
- Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value and Forecast (2019-2030) & (USD Million)
- Figure 16. Global Market Recurrent Glioblastoma Multiforme Treatment Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
- Figure 17. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Region (2019-2030)
- Figure 18. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Region in 2023
- Figure 19. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 20. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 21. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 22. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 23. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 24. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players in 2023

Figure 25. Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023

Figure 26. Global Top 3 Players Recurrent Glioblastoma Multiforme Treatment Market Share in 2023

Figure 27. Global Top 6 Players Recurrent Glioblastoma Multiforme Treatment Market Share in 2023

Figure 28. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Share by Type (2019-2024)

Figure 29. Global Recurrent Glioblastoma Multiforme Treatment Market Share Forecast by Type (2025-2030)

Figure 30. Global Recurrent Glioblastoma Multiforme Treatment Consumption Value Share by Application (2019-2024)

Figure 31. Global Recurrent Glioblastoma Multiforme Treatment Market Share Forecast by Application (2025-2030)

Figure 32. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type (2019-2030)

Figure 33. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application (2019-2030)

Figure 34. North America Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Country (2019-2030)

Figure 35. United States Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 36. Canada Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 37. Mexico Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 38. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type (2019-2030)

Figure 39. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application (2019-2030)

Figure 40. Europe Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Country (2019-2030)

Figure 41. Germany Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 42. France Recurrent Glioblastoma Multiforme Treatment Consumption Value

(2019-2030) & (USD Million)

Figure 43. United Kingdom Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 44. Russia Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 45. Italy Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 46. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type (2019-2030)

Figure 47. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application (2019-2030)

Figure 48. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Region (2019-2030)

Figure 49. China Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 50. Japan Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 51. South Korea Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 52. India Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 53. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 54. Australia Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 55. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type (2019-2030)

Figure 56. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application (2019-2030)

Figure 57. South America Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Country (2019-2030)

Figure 58. Brazil Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 59. Argentina Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 60. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Type (2019-2030)

Figure 61. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Application (2019-2030)



Figure 62. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Consumption Value Market Share by Country (2019-2030)

Figure 63. Turkey Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 64. Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 65. UAE Recurrent Glioblastoma Multiforme Treatment Consumption Value (2019-2030) & (USD Million)

Figure 66. Recurrent Glioblastoma Multiforme Treatment Market Drivers

Figure 67. Recurrent Glioblastoma Multiforme Treatment Market Restraints

Figure 68. Recurrent Glioblastoma Multiforme Treatment Market Trends

Figure 69. Porters Five Forces Analysis

Figure 70. Manufacturing Cost Structure Analysis of Recurrent Glioblastoma Multiforme Treatment in 2023

Figure 71. Manufacturing Process Analysis of Recurrent Glioblastoma Multiforme Treatment

Figure 72. Recurrent Glioblastoma Multiforme Treatment Industrial Chain

Figure 73. Methodology

Figure 74. Research Process and Data Source

## I would like to order

Product name: Global Recurrent Glioblastoma Multiforme Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/GADAB4763A08EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GADAB4763A08EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

